Poniard Pharmaceuticals, Inc. (PARD)

Market Cap	434,756
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	1.50M
EPS (ttm)	-3.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	0
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0100
52-Week Range	0.0100 - 0.1200
Beta	1.23
Analysts	n/a
Price Target	n/a
Est. Earnings Date	n/a

About PARD

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic ...

• Industry: Biotechnology
• IPO Date: Aug 11, 1988
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: PARD

Full Company Profile

News

There is no news available yet.